3615 related articles for article (PubMed ID: 33514427)
1. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
2. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Lanzoni G; Linetsky E; Correa D; Messinger Cayetano S; Alvarez RA; Kouroupis D; Alvarez Gil A; Poggioli R; Ruiz P; Marttos AC; Hirani K; Bell CA; Kusack H; Rafkin L; Baidal D; Pastewski A; Gawri K; Leñero C; Mantero AMA; Metalonis SW; Wang X; Roque L; Masters B; Kenyon NS; Ginzburg E; Xu X; Tan J; Caplan AI; Glassberg MK; Alejandro R; Ricordi C
Stem Cells Transl Med; 2021 May; 10(5):660-673. PubMed ID: 33400390
[TBL] [Abstract][Full Text] [Related]
3. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
[TBL] [Abstract][Full Text] [Related]
4. Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: A case-series.
Alharthy A; Faqihi F; Memish ZA; Balhamar A; Nasim N; Shahzad A; Tamim H; Alqahtani SA; Brindley PG; Karakitsos D
Artif Organs; 2021 May; 45(5):E101-E112. PubMed ID: 33190288
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
Gorman E; Millar J; McAuley D; O'Kane C
Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
[No Abstract] [Full Text] [Related]
6. Umbilical Cord-derived Mesenchymal Stem Cells modulate TNF and soluble TNF Receptor 2 (sTNFR2) in COVID-19 ARDS patients.
Kouroupis D; Lanzoni G; Linetsky E; Messinger Cayetano S; Wishnek Metalonis S; Leñero C; Stone LD; Ruiz P; Correa D; Ricordi C
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4435-4438. PubMed ID: 34227081
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.
Kaffash Farkhad N; Sedaghat A; Reihani H; Adhami Moghadam A; Bagheri Moghadam A; Khadem Ghaebi N; Khodadoust MA; Ganjali R; Tafreshian AR; Tavakol-Afshari J
Stem Cell Res Ther; 2022 Jun; 13(1):283. PubMed ID: 35765103
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.
Häberle H; Magunia H; Lang P; Gloeckner H; Körner A; Koeppen M; Backchoul T; Malek N; Handgretinger R; Rosenberger P; Mirakaj V
J Intensive Care Med; 2021 Jun; 36(6):681-688. PubMed ID: 33663244
[TBL] [Abstract][Full Text] [Related]
9. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
[TBL] [Abstract][Full Text] [Related]
10. Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
Lanzoni G; Linetsky E; Correa D; Alvarez RA; Marttos A; Hirani K; Cayetano SM; Castro JG; Paidas MJ; Efantis Potter J; Xu X; Glassberg M; Tan J; Patel AN; Goldstein B; Kenyon NS; Baidal D; Alejandro R; Vianna R; Ruiz P; Caplan AI; Ricordi C
CellR4 Repair Replace Regen Reprogram; 2020; 8():. PubMed ID: 34164564
[TBL] [Abstract][Full Text] [Related]
11. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Atluri S; Manchikanti L; Hirsch JA
Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
[TBL] [Abstract][Full Text] [Related]
12. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
Meng F; Xu R; Wang S; Xu Z; Zhang C; Li Y; Yang T; Shi L; Fu J; Jiang T; Huang L; Zhao P; Yuan X; Fan X; Zhang JY; Song J; Zhang D; Jiao Y; Liu L; Zhou C; Maeurer M; Zumla A; Shi M; Wang FS
Signal Transduct Target Ther; 2020 Aug; 5(1):172. PubMed ID: 32855385
[TBL] [Abstract][Full Text] [Related]
13. Feasibility Study of Cord Tissue Derived Mesenchymal Stromal Cells in COVID-19-Related Acute Respiratory Distress Syndrome.
Shaz BH; Kraft BD; Troy JD; Poehlein E; Chen L; Cheatham L; Manyara R; Hanafy K; Brown L; Scott M; Palumbo R; Vrionis F; Kurtzberg J
Stem Cells Transl Med; 2023 Apr; 12(4):185-193. PubMed ID: 36929827
[TBL] [Abstract][Full Text] [Related]
14. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.
Zarrabi M; Shahrbaf MA; Nouri M; Shekari F; Hosseini SE; Hashemian SR; Aliannejad R; Jamaati H; Khavandgar N; Alemi H; Madani H; Nazari A; Amini A; Hassani SN; Abbasi F; Jarooghi N; Fallah N; Taghiyar L; Ganjibakhsh M; Hajizadeh-Saffar E; Vosough M; Baharvand H
Stem Cell Res Ther; 2023 Jun; 14(1):169. PubMed ID: 37365605
[TBL] [Abstract][Full Text] [Related]
15. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells.
Shu L; Niu C; Li R; Huang T; Wang Y; Huang M; Ji N; Zheng Y; Chen X; Shi L; Wu M; Deng K; Wei J; Wang X; Cao Y; Yan J; Feng G
Stem Cell Res Ther; 2020 Aug; 11(1):361. PubMed ID: 32811531
[TBL] [Abstract][Full Text] [Related]
16. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
Can A; Coskun H
Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review.
Sadeghi B; Ringdén O; Gustafsson B; Castegren M
Front Immunol; 2022; 13():963445. PubMed ID: 36426365
[TBL] [Abstract][Full Text] [Related]
18. Specific Clinical and Immunological Changes Following Mesenchymal Stem Cell Transplantation in COVID-19-induced Acute Respiratory Distress Syndrome Patients: A Phase-I Clinical Trial.
Kaffash Farkhad N; Sedaghat A; Reihani H; Adhami Moghadam A; Bagheri Moghadam A; Khadem Ghaebi N; Khodadoust MA; Nikpoor AR; Tavakol Afshari J
Iran J Allergy Asthma Immunol; 2022 Dec; 21(6):687-703. PubMed ID: 36640060
[TBL] [Abstract][Full Text] [Related]
19. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
Yang X; Yu Y; Xu J; Shu H; Xia J; Liu H; Wu Y; Zhang L; Yu Z; Fang M; Yu T; Wang Y; Pan S; Zou X; Yuan S; Shang Y
Lancet Respir Med; 2020 May; 8(5):475-481. PubMed ID: 32105632
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19-Induced ARDS Patients: A Case Report.
Kim K; Bae KS; Kim HS; Lee WY
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556900
[No Abstract] [Full Text] [Related]
[Next] [New Search]
